Leukemia Clinical Trial
Official title:
Phase I Study Evaluating the Chemosensitizing Effect of Everolimus Administered With Cytarabine and Daunorubicin in Patients With Acute Myeloid Leukemia in Relapse
Verified date | July 2009 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | Unspecified |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in
different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Everolimus may help cytarabine and daunorubicin work better by
making cancer cells more sensitive to chemotherapy. Giving everolimus together with
cytarabine and daunorubicin may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when
given together with cytarabine and daunorubicin in treating patients with relapsed acute
myeloid leukemia.
Status | Recruiting |
Enrollment | 21 |
Est. completion date | |
Est. primary completion date | April 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
DISEASE CHARACTERISTICS: Inclusion criteria: - Diagnosis of de novo or secondary acute myeloid leukemia meeting the following criterion: - Relapse > 1 year after obtaining complete remission (any prior treatment allowed) Exclusion criteria: - Philadelphia chromosome-positive disease in blast crisis - FAB M3, M6, or M7 disease PATIENT CHARACTERISTICS: Inclusion criteria: - Life expectancy = 4 weeks - Transaminases = 5 times normal - Creatinine = 2 times normal - Bilirubin = 3 times normal (except if visceral involvement present) - Alkaline phosphatase or gamma-glutamyltransferase = 5 times normal - Not pregnant or nursing - Negative pregnancy test - Fertile patients of must use effective contraception during and for = 28 days after completion of study therapy Exclusion criteria: - FEV1 < 30% - Active uncontrolled or viral pulmonary infection - Serious psychiatric disorders not related to leukemia or any condition that would prohibit comprehension of the study - HIV-positive - Other concurrent malignancy except noninvasive skin cancer or carcinoma in situ - Patients who are incarcerated or under supervision or trusteeship PRIOR CONCURRENT THERAPY: Inclusion criteria: - See Disease Characteristics Exclusion criteria: - Prior experimental medication within the past 4 weeks |
Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Hopital Cochin | Paris |
Lead Sponsor | Collaborator |
---|---|
Institut de Recherche Clinique sur les Cancers et le Sang |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose of everolimus | Yes | ||
Primary | Toxicity | Yes | ||
Secondary | Activation of PI3K/AKT and mTORC 1 in leukemic blasts | No | ||
Secondary | Pharmacokinetics of everolimus | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |